Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
/ metabolism
Chemotherapy, Adjuvant
Datasets as Topic
Disease Progression
Disease-Free Survival
Drug Resistance, Neoplasm
/ genetics
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Humans
Kaplan-Meier Estimate
Male
MicroRNAs
/ metabolism
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Nomograms
Prostate
/ pathology
Prostatectomy
Prostatic Neoplasms
/ genetics
RNA, Messenger
/ metabolism
ROC Curve
Reproducibility of Results
Risk Assessment
/ methods
microRNA
prostate cancer
recurrence-free survival
Journal
International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
06
2020
accepted:
02
11
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Recurrence is a major problem for prostate cancer patients, thus, identifying prognosis-related markers to evaluate clinical outcomes is essential. Here, we established a fifteen-miRNA-based recurrence-free survival (RFS) predicting signature based on the miRNA expression profile extracted from The Cancer Genome Atlas (TCGA) database by the LASSO Cox regression analysis. The median risk score generated by the signature in both the TCGA training and the external Memorial Sloan-Kettering Cancer Center (MSKCC) validation cohorts was employed and the patients were subclassified into low- and high-risk subgroups. The Kaplan-Meier plot and log-rank analyses showed significant survival differences between low- and high-risk subgroups of patients (TCGA, log-rank
Identifiants
pubmed: 33390797
doi: 10.7150/ijms.49412
pii: ijmsv18p0284
pmc: PMC7738977
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
MicroRNAs
0
RNA, Messenger
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
284-294Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
J Extracell Vesicles. 2019 Jan 29;8(1):1567219
pubmed: 30728923
Cancers (Basel). 2018 May 21;10(5):
pubmed: 29883412
Chin J Cancer. 2011 Jun;30(6):381-91
pubmed: 21627860
Eur Urol. 2020 Feb;77(2):180-188
pubmed: 31606332
Oncol Lett. 2019 Mar;17(3):2777-2787
pubmed: 30854052
J Cancer. 2019 Oct 6;10(23):5793-5804
pubmed: 31737116
Oncol Lett. 2019 Mar;17(3):2687-2694
pubmed: 30854042
Cancer Cell Int. 2018 Apr 4;18:54
pubmed: 29632436
Nat Commun. 2015 Oct 15;6:8640
pubmed: 26468775
Cancers (Basel). 2018 May 31;10(6):
pubmed: 29857525
Asian Pac J Cancer Prev. 2015;16(14):6111-6
pubmed: 26320504
Gene. 2019 May 30;699:125-134
pubmed: 30849543
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Clin Cancer Res. 2009 Aug 1;15(15):4792-8
pubmed: 19638458
Medicine (Baltimore). 2019 Mar;98(9):e14569
pubmed: 30817574
Int J Mol Sci. 2019 Mar 06;20(5):
pubmed: 30845775
J Natl Cancer Inst. 1995 Aug 2;87(15):1114-25
pubmed: 7674315
Cancer. 2012 Jun 15;118(12):3062-70
pubmed: 22006014
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154
pubmed: 31647101
Comput Biol Med. 2017 Dec 1;91:159-167
pubmed: 29078093
Respir Res. 2019 Mar 4;20(1):48
pubmed: 30832674
Curr Opin Genet Dev. 1998 Feb;8(1):14-20
pubmed: 9529600
Cancers (Basel). 2018 May 18;10(5):
pubmed: 29783720
Cancer Biomark. 2019;24(3):299-305
pubmed: 30829615
Front Genet. 2020 Feb 04;10:1402
pubmed: 32117427
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Mutagenesis. 2019 May 29;34(2):127-133
pubmed: 30852614
Gene. 2018 Aug 20;668:107-113
pubmed: 29775754
Semin Liver Dis. 2015 Feb;35(1):3-11
pubmed: 25632930
Oncogene. 2010 Oct 21;29(42):5724-8
pubmed: 20676129
Neuromolecular Med. 2009;11(3):208-22
pubmed: 19731102
Mol Med Rep. 2019 Mar;19(3):1753-1760
pubmed: 30628692
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Oncol Lett. 2019 Mar;17(3):2657-2668
pubmed: 30854040
Cells. 2018 Aug 11;7(8):
pubmed: 30103495
Chin J Cancer. 2015 Jan;34(1):28-40
pubmed: 25556616
Mol Med Rep. 2019 Apr;19(4):2599-2610
pubmed: 30816460
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):152-6
pubmed: 23271766
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Cancers (Basel). 2018 Jun 27;10(7):
pubmed: 29954119
Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):11-24
pubmed: 29141851
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell Physiol Biochem. 2018;49(4):1539-1550
pubmed: 30212824
J Clin Med. 2019 Jan 23;8(2):
pubmed: 30678026
Mol Ther Nucleic Acids. 2019 Jun 7;16:91-104
pubmed: 30852380
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Science. 1994 Dec 23;266(5193):1954-6
pubmed: 7801120
Cancers (Basel). 2018 Jul 28;10(8):
pubmed: 30060597
Oncotarget. 2019 Jan 29;10(9):966-981
pubmed: 30847025
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Sci Rep. 2019 Dec 23;9(1):19619
pubmed: 31873114
Int J Clin Exp Pathol. 2018 Aug 01;11(8):3969-3976
pubmed: 31949785
Nature. 1999 Jun 17;399(6737):700-4
pubmed: 10385124
Nucleic Acids Res. 2009 Jan;37(Database issue):D105-10
pubmed: 18996891
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799511
Oncol Lett. 2019 Mar;17(3):2631-2638
pubmed: 30854038
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Death Dis. 2014 Jul 17;5:e1325
pubmed: 25032848
Cancers (Basel). 2018 Jun 08;10(6):
pubmed: 29890631
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528